Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Abdullah Kaplan, Emna Abidi, Ahmed F. El‐Yazbi, et al.
Heart Failure Reviews (2018) Vol. 23, Iss. 3, pp. 419-437
Closed Access | Times Cited: 97

Showing 26-50 of 97 citing articles:

SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
Xiaodan Wang, Jingyu Ni, Rui Guo, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 3, pp. 961-980
Closed Access | Times Cited: 31
Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK
Kun‐Ling Tsai, Pei‐Ling Hsieh, Wan-Ching Chou, et al.
Cell & Bioscience (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 28
Associação entre diabetes e insuficiência cardíaca: mecanismos, fatores de risco e implicações clínicas
Roger Antônio Morais Queiroz, Hanna Victoria Marinho Oliveira Garcia, Geraldo Magela Pereira, et al.
Caderno Pedagógico (2025) Vol. 22, Iss. 1, pp. e13212-e13212
Closed Access
Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis
I-Chia Liang, Hsun-Hao Chang, Yu-Jou Lai, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 202-202
Open Access
Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
Aiswarya Jaiswal, Poonam Yadav, Pushkar Singh Rawat, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis
U Bhalraam, Rathna B Veerni, Sophie Paddock, et al.
European Journal of Preventive Cardiology (2025)
Open Access
Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure
Omar Mourad, Shabana Vohra, Sara S. Nunes
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
Giuseppe Cianciolo, Antonio De Pascalis, Lorenzo Gasperoni, et al.
Molecules (2020) Vol. 25, Iss. 12, pp. 2757-2757
Open Access | Times Cited: 31
SGLT2 inhibitors, sodium and off-target effects: an overview
Antonio De Pascalis, Giuseppe Cianciolo, Irene Capelli, et al.
Journal of Nephrology (2020) Vol. 34, Iss. 3, pp. 673-680
Closed Access | Times Cited: 29
Review of cardiovascular outcomes trials of sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
Emily J. North, Jonathan Newman
Current Opinion in Cardiology (2019) Vol. 34, Iss. 6, pp. 687-692
Open Access | Times Cited: 28
SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review
Anirudh Manoj, Subham Das, A Ramachandran, et al.
Future Medicinal Chemistry (2020) Vol. 12, Iss. 21, pp. 1961-1990
Closed Access | Times Cited: 26
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
John S. Clemmer, Taylor J. Ward, Seth T. Lirette
ESC Heart Failure (2023) Vol. 10, Iss. 3, pp. 2010-2018
Open Access | Times Cited: 7
Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions
Cédric Neutel, Callan D. Wesley, Melissa Van Praet, et al.
Vascular Pharmacology (2023) Vol. 152, pp. 107212-107212
Open Access | Times Cited: 7
Empagliflozin improves cardiac energetics during ischaemia/reperfusion by directly increasing cardiac ketone utilization
Dylan Chase, Thomas R. Eykyn, Michael J. Shattock, et al.
Cardiovascular Research (2023) Vol. 119, Iss. 16, pp. 2672-2680
Open Access | Times Cited: 7
Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure
Chen Gao, Shuxun Ren, Junyi Yu, et al.
JACC Basic to Translational Science (2019) Vol. 4, Iss. 2, pp. 161-172
Open Access | Times Cited: 22
Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice
Ryan Kurtz, Andrew E. Libby, Bryce A. Jones, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5675-5675
Open Access | Times Cited: 12
Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects
Li Xiao, Yue Yao, Luoyifan Zhou, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 2
Open Access | Times Cited: 2
Targeted HFpEF therapy based on matchmaking of human and animal models
Arantxa Barandiarán Aizpurua, Blanche Schroen, Marc van Bilsen, et al.
AJP Heart and Circulatory Physiology (2018) Vol. 315, Iss. 6, pp. H1670-H1683
Open Access | Times Cited: 17
Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease
Aaqib H. Malik, Srikanth Yandrapalli, Michael D. Goldberg, et al.
Cardiology in Review (2019) Vol. 28, Iss. 3, pp. 116-124
Closed Access | Times Cited: 17
Sodium–glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure
Dhan Bahadur Shrestha, Pravash Budhathoki, Yub Raj Sedhai, et al.
Journal of Cardiovascular Pharmacology (2021) Vol. 78, Iss. 4, pp. 501-514
Closed Access | Times Cited: 13
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Ioan Ţilea, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 12, pp. 1249-1249
Open Access | Times Cited: 13
Diabetes mellitus and heart failure: an update on pathophysiology and therapy
Nicola Potere, Marco Giuseppe Del Buono, Alessandra Vecchié, et al.
Minerva Cardiology and Angiology (2022) Vol. 70, Iss. 3
Closed Access | Times Cited: 9
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
М. В. Краснова, А. Н. Куликов, Sergey V. Okovityi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2020) Vol. 393, Iss. 9, pp. 1649-1658
Closed Access | Times Cited: 13
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Chris Wai Hang Lo, Yue Fei, Bernard Man Yung Cheung
Cardiac failure review (2021) Vol. 7
Open Access | Times Cited: 12
What Role do Mitochondria Have in Diastolic Dysfunction? Implications for Diabetic Cardiomyopathy and Heart Failure With Preserved Ejection Function
Martin G. McCandless, Raffaele Altara, George W. Booz, et al.
Journal of Cardiovascular Pharmacology (2022) Vol. 79, Iss. 4, pp. 399-406
Closed Access | Times Cited: 8

Scroll to top